Taurine 8 pp 3-18 | Cite as

Neuropsychopharmacological Actions of Taurine

  • Shailesh P. BanerjeeEmail author
  • Andre Ragnauth
  • Christopher Y. Chan
  • Mervan S. Agovic
  • Vincent Sostris
  • Iman Jashanmal
  • Louis Vidal
  • Eitan Friedman
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 775)


Taurine, an endogenous amino sulfonic acid, exhibits numerous neuropsychopharmacological activities. Previous studies in our laboratory have shown that it is an effective anti-cataleptic and neuro-protective agent. Current investigations show that acute or chronic administration of psychotropic drug cocaine may increase extracellular release of endogenous taurine which may protect against deleterious effects of the substances of abuse. Taurine administration was found to prevent cocaine-induced addiction by suppressing spontaneous locomotor activity and conditioned place preference. Taurine markedly delayed tail-flick response in rats which was significantly different from that in the group of animal receiving the same volume of saline, thereby indicating that taurine is a potentially valuable analgesic agent. Both taurine and endomorphin-1 were found to suppress the delayed broad negative evoked field potentials in anterior insular cortex (upper layer 5) by partially inhibiting NMDA receptor system. Thus, taurine is a unique psychopharmacological compound with potential for a variety of therapeutic uses including as a neuro-protective, anti-cataleptic, anti-addicting, and analgesic agent.


NMDA Receptor Conditioned Place Preference NMDA Receptor Antagonist Chronic Cocaine Psychomotor Stimulant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.





Gama-amino-butyric acid


DL-2-Amino-5-phosphonopentanoic acid


Conditioned place preference



This work was supported by DAO18055 grant from NIDA and by PSC-CUNY 41-582 grant.


  1. Agovic MS, Yablonsky-Alter E, Lidsky TI, Banerjee SP (2008) Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol 587:181–186PubMedCrossRefGoogle Scholar
  2. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioral anti depressants responses. Nature 475:91–95PubMedCrossRefGoogle Scholar
  3. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI (1995) Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport 6:2500–2504PubMedCrossRefGoogle Scholar
  4. Chan CY, Sun HS, Shah SM, Agovic MS, Ho I, Friedman E, Banerjee SP (2012) Direct interaction of taurine with the NMDA glutamate receptor sub-type via multiple mechanisms. 18th annual Taurine meeting. Marrakesh, MoroccoGoogle Scholar
  5. Gupta A, Devi LA, Gomes I (2011) Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem 119:294–302PubMedCrossRefGoogle Scholar
  6. Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565–598PubMedCrossRefGoogle Scholar
  7. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855–876PubMedCrossRefGoogle Scholar
  8. Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nat Rev Neurosci 8:844–858PubMedCrossRefGoogle Scholar
  9. Lidsky TI, Banerjee SP (1992) Clozapine’s mechanisms of action: non-dopaminergic activity rather than anatomical selectivity. Neurosci Lett 139:100–103PubMedCrossRefGoogle Scholar
  10. Lidsky TI, Banerjee SP (1993) Acute administration of haloperidol enhances dopaminergic transmission. J Pharmacol Exp Ther 265:1193–1198PubMedGoogle Scholar
  11. Lidsky TI, Banerjee SP (1996) Contribution of glutamatergic dysfunction to schizophrenia. Drug News & Perspectives 9:453–459PubMedCrossRefGoogle Scholar
  12. Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP (1993) Anti-glutamatergic effects of clozapine. Neurosci Lett 163:155–158PubMedCrossRefGoogle Scholar
  13. Lidsky TI, Schneider JS, Zuck LG, Yablonsky-Alter E, Banerjee SP (1994) GM1 ganglioside attenuates changes in neurochemistry and behavior caused by repeated haloperidol administration. Neurodegeneration 3:135–140PubMedCrossRefGoogle Scholar
  14. Lidsky TI, Schneider JS, Yablonsky-Alter E, Zuck LG, Banerjee SP (1995) Taurine prevents haloperidol-induced changes in striatal neurochemistry and behavior. Brain Res 686:104–106PubMedCrossRefGoogle Scholar
  15. Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP (1997) Antipsychotic drug effects on glutamatergic activity. Brain Res 764:46–52PubMedCrossRefGoogle Scholar
  16. Luscher C (2012) Drugs of abuse. In: Katsung BG et al (eds) Basic and clinical pharmacology. The McGraw Hill Companies Inc., New York, pp 565–580Google Scholar
  17. Martin RP, Patel S, Swift MR (2012) Pharmacology of drugs of abuse. In: Golan DE, Tashjian HA, Armstrong JE, Armstrong WA (eds) Principles of pharmacology. Lippincott Williams & Wilkins, Philadelphia, PA, pp 284–309Google Scholar
  18. Martin RP, Patel S, Swift MR (2012) Pharmacology of drugs of abuse. In: Golan DE, Tashjian HA, Armstrong JE, Armstrong WA (eds) Principles of pharmacology. Lippincott Williams & Wilkins, Philadelphia, PA, pp 284–309Google Scholar
  19. Mathisen LC, Skjelbred P, Skoglund LA, Oye I (1995) Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 61:215–220PubMedCrossRefGoogle Scholar
  20. Mochanova SM, Oja SS, Saransaari P (2007) Inhibitory effect of taurine on veratridine-evoked D-[3H]aspartate release from murine corticostriatal slices: involvement of chloride channels and mitochondria. Brain Res 1130:95–102PubMedCrossRefGoogle Scholar
  21. Okamoto K, Kimura H, Sakai Y. (1983) Taurine-induced increase of the Cl-conductance of cerebellar Purkinje cell dendrites in vitro. Brain Res.259:319–23.Google Scholar
  22. Okamoto K, Kimura H, Sakai Y (1983b) Evidence for taurine as an inhibitory neurotransmitter in cerebellar stellate interneurons: selective antagonism by TAG (6-aminomethyl-3-methyl-4H,1,2,4-benzothiadiazine-1,1-dioxide). Brain Res 265:163–168PubMedCrossRefGoogle Scholar
  23. Quinn MR, Miller CL (1992) Taurine allosterically modulates flunitrazepam binding to synaptic membranes. J Neurosci Res 33:136–141PubMedCrossRefGoogle Scholar
  24. Ragnauth A, Znamensky V, Moroz M, Bodnar RJ (2000) Analysis of dopamine receptor antagonism upon feeding elicited by mu and delta opioid agonists in the shell region of the nucleus accumbens. Brain Res 877:65–72PubMedCrossRefGoogle Scholar
  25. Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci U S A 198:1958–1963CrossRefGoogle Scholar
  26. Ragnauth AK, Devidze N, Moy V, Finley K, Goodwillie A, Kow LM, Muglia LJ, Pfaff DW (2005) Female oxytocin gene-knockout mice, in a semi-natural environment, display exaggerated aggressive behavior. Genes Brain Behav 4:229–239PubMedCrossRefGoogle Scholar
  27. Rodriguiz RM, Gadnidze K, Ragnauth A, Dorr N, Yanagisawa M, Wetsel WC, Devi LA (2008) Animals lacking endothelin-converting enzyme-2 are deficient in learning and memory. Genes Brain Behav 7:418–426PubMedCrossRefGoogle Scholar
  28. Schumacher MA, Basbaum AI, Way WL (2012) Opioid analgesics and antagonists. In: Katzung BG et al (eds) Basic and clinical pharmacology. The McGraw Hill Companies Inc., New York, pp 543–564Google Scholar
  29. Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol 182:313–333Google Scholar
  30. Spinella M, Znamensky V, Moroz M, Ragnauth A, Bodnar RJ (1999) Actions of NMDA and cholinergic receptor antagonists in the rostral ventromedial medulla upon beta-endorphin analgesia elicited from the ventrolateral periaqueductal gray. Brain Res 829:151–159PubMedCrossRefGoogle Scholar
  31. Tverskoy M, Oz Y, Isakson A, Finger J, Bradley EL Jr, Kissin I (1994) Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyper-algesia. Anesth Analg 78:205–209PubMedCrossRefGoogle Scholar
  32. Yablonsky-Alter E, Gashi E, Lidsky TI, Wang HY, Banerjee SP (2005) Clozapine protection against gestational cocaine-induced neurochemical abnormalities. J Pharmacol Exp Ther 312:297–302PubMedCrossRefGoogle Scholar
  33. Yablonsky-Alter E, Agovic MS, Gashi E, Lidsky TI, Friedman E, Banerjee SP (2009) Cocaine challenge enhances release of neuroprotective amino acid taurine in the striatum of chronic cocaine treated rats: a micro-dialysis study. Brain Res Bull 79:215–218PubMedCrossRefGoogle Scholar
  34. Yarbrough GG, Singh DK, Taylor DA (1981) Neuropharmacological characterization of a taurine antagonist. J Pharmacol Exp Ther 3:604–613Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Shailesh P. Banerjee
    • 1
    • 2
    Email author
  • Andre Ragnauth
    • 1
    • 3
  • Christopher Y. Chan
    • 1
    • 2
  • Mervan S. Agovic
    • 1
    • 2
    • 4
  • Vincent Sostris
    • 1
    • 2
  • Iman Jashanmal
    • 1
    • 3
  • Louis Vidal
    • 1
  • Eitan Friedman
    • 1
    • 2
  1. 1.Department of Physiology, Pharmacology and NeuroscienceSophie Davis School of Biomedical Education at CCNY, City University of New YorkNew YorkUSA
  2. 2.Neuroscience Subprogram, Doctoral Programs in BiologyGraduate Center of the City University of New YorkNew YorkUSA
  3. 3.Neuroscience Subprogram, Doctoral Programs in PsychologyGraduate Center of the City University of New YorkNew YorkUSA
  4. 4.Department of BiologyBronx Community College, The City University of New YorkNew YorkUSA

Personalised recommendations